United Theranostics Announces Significant Funding for Growth
United Theranostics has announced a major development in its efforts to enhance patient access to innovative cancer therapies. The company recently finalized a $15 million senior debt facility, with financial backing from Old National Bank. This partnership is set to significantly bolster United Theranostics' ability to scale its operations and reach more patients across the nation.
Expanding the Clinical Network
The funds acquired through this debt facility will primarily be utilized to establish a network of up to eight new clinics throughout the country. United Theranostics is committed to providing patients with access to approved radiopharmaceutical therapies as well as opportunities to participate in clinical trials for novel treatments. By expanding its footprint, the company hopes to create a more comprehensive network to support communities with specialized cancer care.
Vision for the Future
According to Rob Cherney, CEO of United Theranostics, this financial partnership is critical for the company's growth. He emphasized that the clinics will be designed based on their successful flagship site and new state-of-the-art facility, both of which highlight United Theranostics' patient-focused approach. Cherney stated, “We are excited about the rapid growth we anticipate in the coming years, particularly through 2026. Our aim is to provide cutting-edge therapies to patients within their communities.”
Leadership Team Enhancements
United Theranostics was founded by an esteemed group of medical professionals including Dr. Michael Morris, Dr. Babak Saboury, and Dr. Eliot Siegel. Recently, the team has been strengthened with the addition of Dr. Munir Ghesani, who serves as Chief Medical Officer and is responsible for leading the new clinic in Princeton.
Innovative Cancer Treatment Solutions
This expansion demonstrates United Theranostics' commitment to addressing the increasing demand for advanced radiation therapies and molecular imaging services. By creating additional clinics, they will not only ease the burden of travel for patients needing these specialized treatments but also ensure that cutting-edge therapies are accessible across diverse regions.
Commitment to Patient-Centric Care
At its core, United Theranostics is devoted to transforming the landscape of cancer treatment through patient-centric practices. The company prides itself on providing the latest advancements in radiopharmaceutical therapy in an environment that prioritizes patient comfort and well-being. This focus is integral to their mission of making these therapies widely available, particularly in outpatient settings.
Frequently Asked Questions
What is the purpose of the $15 million funding?
The funding will be used to expand the network of clinics that provide advanced cancer treatments to patients across the country.
How many new clinics does United Theranostics plan to open?
The company plans to establish up to eight new clinics in the upcoming year.
Who are the key leaders behind United Theranostics?
United Theranostics was founded by Dr. Michael Morris, Dr. Babak Saboury, and Dr. Eliot Siegel, with Dr. Munir Ghesani joining as Chief Medical Officer.
What types of treatments will the new clinics offer?
The new clinics will provide approved radiopharmaceutical therapies as well as access to clinical trials for innovative cancer treatments.
What is the mission of United Theranostics?
The company aims to increase access to cutting-edge radiopharmaceutical therapies and advanced molecular imaging in a patient-friendly environment.
